Cosciens BiopharmaCSCIF +3.90%60 Return-on-Tangible-Equity is 449.17% as of Mar. 2026. GuruFocus rates CSCIF with a GF Score™ of 60/100 and a GF Value™ of $2.39 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,202 Biotechnology companies, Cosciens Biopharma ranks better than 95.17% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cosciens Biopharma's annualized net income for the quarter that ended in Mar. 2026 was $43.03 Mil. Cosciens Biopharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $9.58 Mil. Therefore, Cosciens Biopharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 449.17%.
The historical rank and industry rank for Cosciens Biopharma's Return-on-Tangible-Equity or its related term are showing as below:
CSCIF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -118.83 Med: -2.89 Max: 48.09
Current: 48.09
During the past 13 years, Cosciens Biopharma's highest Return-on-Tangible-Equity was 48.09%. The lowest was -118.83%. And the median was -2.89%.
CSCIF's Return-on-Tangible-Equity is ranked better than 95.17% of 1202
companies
in the Biotechnology industry
Industry Median: -42.435
vs CSCIF: 48.09
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cosciens Biopharma Return-on-Tangible-Equity Related Terms
Cosciens Biopharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 449.17% mean?
Cosciens Biopharma (CSCIF) has a Return-on-Tangible-Equity of 449.17% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cosciens Biopharma and its competitors. According to the industry distribution chart, Cosciens Biopharma ranks #58 out of 1202 companies in the Biotechnology industry, placing it in the top 4.8%.
Is Cosciens Biopharma's Return-on-Tangible-Equity too high?
Cosciens Biopharma's current Return-on-Tangible-Equity is 449.17%. Based on the distribution chart, Cosciens Biopharma ranks #58 out of 1202 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #58 out of 1202 companies for Return-on-Tangible-Equity. This places Cosciens Biopharma in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Return-on-Tangible-Equity is 449.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.39, compared to a current price of $2.13 — trading 10.9% below its estimated fair value. The current Return-on-Tangible-Equity is 449.17%. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Return-on-Tangible-Equity is 449.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $2.13 is trading 10.9% below its estimated GF Value™ of $2.39.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Return-on-Tangible-Equity: 449.17%
GF Value™: $2.39 vs. price of $2.13 (10.9% below fair value)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score
Get the complete analysis for CSCIF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
